Our research team has identified a key pathway that regulates tumor growth in solid cancers. This discovery opens new avenues for therapeutic intervention using our small molecule library.
The study, published today in Nature Medicine, details how Nexalife's proprietary compound NX-403 selectively degrades a previously "undruggable" oncoprotein.
"This represents a significant leap forward in our understanding of cancer biology," said Dr. Elena Rostova, CSO. "We are now advancing into lead optimization and hope to nominate a development candidate by the end of the year."